SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of January 2006
FRESENIUS MEDICAL CARE CORPORATION
(Translation of registrant's name into English)
Else-Kroner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82
Effective January 1, 2006, National Medical Care, Inc. ("NMC"), a
wholly-owned subsidiary of Fresenius Medical Care AG (the "Company") entered
into an Agreement (the "Agreement") with Amgen, Inc. ("Amgen") for the purchase
of Epoetin alfa ("EPOGEN") and Darbepoetin alfa ("Aranesp" and together with
EPOGEN, the "Products"). The Agreement provides for discounted pricing for the
Products purchased by NMC and its affiliates. The Agreement commences January 1,
2006 and expires December 31, 2007.
This Report on Form 6-K shall be incorporated by reference in the
Registration Statement on Form F-4 (Registration No. 333-128899) filed October
7, 2005 by the Company and shall be part thereof and the prospectus included
therein from the date on which this report is filed, to the extent not
superseded by documents or reports subsequently filed or furnished by the
Company with the U.S. Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DATE: January 3, 2006
FRESENIUS MEDICAL CARE
AKTIENGESELLSCHAFT
By: /s/ DR. BEN LIPPS
----------------------------------------
Name: Dr. Ben Lipps
Title: Chief Executive Officer and
Chairman of the Management Board
By: /s/ LAWRENCE A. ROSEN
----------------------------------------
Name: Lawrence A. Rosen
Title: Chief Financial Officer